Servier announces the appointment of Nicolas Garnier as Chief Patient Officer, effective from December 4, 2023. He takes over from Bertrand Renaud, who will retire at the end of January 2024.
Reporting to Arnaud Lallouette, Executive Vice President Global Medical & Patient Affairs, Nicolas Garnier leads Global Patient Affairs department, whose mission is to integrate the voice of the patient at each stage of the drug lifecycle. His main objective is to coordinate, promote and develop patient engagement among all Group employees and global subsidiaries, working closely with patients and the organizations that represent them.
Nicolas completed a Degree in Cellular Biology and Physiology and a Specialized Master’s in Genetics at Université Paris Cité, followed by a Ph.D. in Experimental Medicine (Oncology) at McGill University in Montreal and a post-doc in Genomics (Pediatric Oncology) at the Université de Montréal Faculty of Medicine. From the start of this year and before joining the Servier Group, Nicolas was Head of Patient Advocacy in all therapeutic areas of Pfizer clinical studies.
Arnaud Lallouette, Executive Vice President of Global Medical & Patient Affairs, said, “I am delighted about the arrival of Nicolas Garnier, who will leverage his strong international experience gained in patient engagement and the understanding of their needs. He will also enable us to accelerate our desire to support patients in fighting their disease, giving them a central place in the diagnostic process, the development of new therapeutic solutions, and the adherence to their treatment.”
